RVR Group inks agreement with UKM to conduct clinical trials
Posted on 25 July 2013 - 01:45pm
Last updated on 25 July 2013 - 02:16pm
NEW YORK (July 25, 2013): The RVR Group, a Malaysian company headed by Mac Vajuram and Dr Avijit Roy, both Malaysians living in the United States, signed a memorandum of agreement with Universiti Kebangsaan Malaysia (UKM) to conduct clinical trials on RVR's diagnostic kit developed to test dengue fever.
The clinical trials have to be conducted on a broad-based constituency of dengue-fever patients so that the accuracy and effectiveness of the diagnostic testing kit could be established.
Meanwhile, RVR Holdings, the financial arm of RVR Diagnostics, signed an additional Memorandum of Understanding with Kuala Lumpur based Chulia Facilities Management Sdn Bhd.
In an interview with Bernama after the signing ceremony, Vajuram said after approval is sought from the FDA, the diagnostic kit would be the first ever to be developed for testing dengue fever.
"There are similar kits already existing for HIV, venereal diseases and other health problems, but dengue fever that afflicts many Asian countries could be tested for the first time by such a kit," he said.
Vajuram added the diagnosis was developed in the United States by Chembio, a New York-based company, with which RVR has licensing agreement for commercial use in Malaysia.
NIH has all the antigens and antisera to make a DPP. I think one of the guys is Dr. Whitehead. CRL looked at the different Dengue recombinant antigens when I was there in 2004. There are 5 Dengue strains of virus, three of which are serious pathogens. Dengue was introduced into Central America more than 10 years ago and is migrating North.